# A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

> **NCT04576208** · PHASE2 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** TAK-788
- **DRUG:** Antidiarrheal prophylaxis

## Key facts

- **NCT ID:** NCT04576208
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-30
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision (no safety or efficacy concerns)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04576208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04576208, "A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04576208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*